We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Retatrutide is an investigational, once-weekly "triple G" (GIP, GLP-1, and Glucagon) receptor agonist developed by Eli Lilly for obesity and type 2 diabetes. Clinical trials show it provides superior weight loss (up to ~24–28.7% over 68 weeks) compared to current drugs, with Phase 3 trials concluding in early 2026.